Goodwin Procter is representing longtime client Albany Molecular Research, Inc. (NASDAQ: AMRI) in its acquisition of Euticals, a leading European player in custom synthesis and the manufacturing of active pharmaceutical ingredients (APIs).
The transaction, valued at approximately $358 million, positions AMRI as one of the largest independent developers and suppliers of APIs. It will also expand AMRI’s presence in Europe, as Euticals operates a network of API facilities primarily in Italy, Germany and France, in addition to the U.S.
AMRI is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, its key business segments include discovery and development services, active pharmaceutical ingredients, and drug product manufacturing.
Euticals is a privately-held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of APIs. It operates a network of API facilities primarily in Italy, Germany, U.S. and France.
The Goodwin team representing AMRI in this transaction was led by partners Stuart Cable, Danielle Lauzon, Jacqueline Mercier and Jennifer Bralower.
For additional information, please read AMRI’s press release.